1. Home
  2. MRSN vs KORE Comparison

MRSN vs KORE Comparison

Compare MRSN & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRSN
  • KORE
  • Stock Information
  • Founded
  • MRSN 2001
  • KORE 2003
  • Country
  • MRSN United States
  • KORE United States
  • Employees
  • MRSN N/A
  • KORE N/A
  • Industry
  • MRSN Biotechnology: Pharmaceutical Preparations
  • KORE Telecommunications Equipment
  • Sector
  • MRSN Health Care
  • KORE Consumer Discretionary
  • Exchange
  • MRSN Nasdaq
  • KORE Nasdaq
  • Market Cap
  • MRSN 37.0M
  • KORE 39.3M
  • IPO Year
  • MRSN 2017
  • KORE N/A
  • Fundamental
  • Price
  • MRSN $7.24
  • KORE $2.16
  • Analyst Decision
  • MRSN Strong Buy
  • KORE Hold
  • Analyst Count
  • MRSN 4
  • KORE 2
  • Target Price
  • MRSN $63.67
  • KORE $2.75
  • AVG Volume (30 Days)
  • MRSN 138.9K
  • KORE 14.9K
  • Earning Date
  • MRSN 08-13-2025
  • KORE 08-14-2025
  • Dividend Yield
  • MRSN N/A
  • KORE N/A
  • EPS Growth
  • MRSN N/A
  • KORE N/A
  • EPS
  • MRSN N/A
  • KORE N/A
  • Revenue
  • MRSN $34,769,000.00
  • KORE $285,636,000.00
  • Revenue This Year
  • MRSN N/A
  • KORE $4.66
  • Revenue Next Year
  • MRSN $1.03
  • KORE $6.71
  • P/E Ratio
  • MRSN N/A
  • KORE N/A
  • Revenue Growth
  • MRSN 16.14
  • KORE 0.24
  • 52 Week Low
  • MRSN $5.21
  • KORE $1.10
  • 52 Week High
  • MRSN $70.75
  • KORE $4.88
  • Technical
  • Relative Strength Index (RSI)
  • MRSN 48.99
  • KORE 39.68
  • Support Level
  • MRSN $5.21
  • KORE $2.26
  • Resistance Level
  • MRSN $7.68
  • KORE $2.49
  • Average True Range (ATR)
  • MRSN 0.54
  • KORE 0.16
  • MACD
  • MRSN 0.12
  • KORE -0.02
  • Stochastic Oscillator
  • MRSN 81.04
  • KORE 14.44

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

About KORE KORE Group Holdings Inc.

Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.

Share on Social Networks: